Advertisement

Metabolic Host Factors as Modifiers of Reactive Intermediates Possibly Involved in Human Cancer

  • E. Hietanen
  • H. Bartsch
  • H. Vainio
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 197)

Abstract

The current theory of the mechanism of chemical carcinogenesis is that precarcinogens are metabolized by mostly mixed-function oxidases into rteacive intermediates that act as ultimate carcinogens (Miller and Miller, 1966) the liver and in extrahepatic organs (Vainio and Hietanen, 1980). The Wide variation among human individuals in the enzymes involved in metabolic actvation of xenobiotics may be due in part to host factors and to interactins with environmental exposures (Table 1; Farrell et al., 1979; Sotaniemi et al., 1980). These factors include different life styles, genetic differences and the various clinical and subclinical diseases that may alter liver metabolism in man during his relatively long life span (Vesell, 1982). Exposure to cancer-causing foreign compounds appears to beone of the most important environmentalrisk factors whereas the host-response to xenobiotics may modify individual risk for cancer arising from such exposures. Some current evidence for such an hypothesis is rerieved herein.

Keywords

Reactive Intermediate Host Factor Probe Drug Isozyme Pattern Aryl Hydrocarbon Hydroxylase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ayesh, R., Idle, J. R., Ritchie, J. C., Crothers, M. J., and Hetzel, M. R. 1984, Metabolic oxidation phenotypes as markers for susceptibility to lung cancer, Nature, 312: 169.PubMedCrossRefGoogle Scholar
  2. Bartsch, H., Aitio, A., Camus, A. M., Malaveille, C., Ohshima, H., Pignatelli, B., and Sabadie, N., 1982 Carcinogen-metabolizing enzymes and susceptibility to chemical carcinogens, in, “Host Factors in Human Carcinogenesis (IARC Scientific Publications No. 39), International Agency for Reseach on Cancer, H. Bartsch, and B. Armstrong, eds., Lyon, p. 337.Google Scholar
  3. Bartsch, H., Ohshima, H., Munoz, N., Pignatelli, B., Friesen, M., O’Neill, J., Crespi, M., and Lu, S. H., 1983, Assessment of endogenous nitrosation in humans in relation to the risk of cancer of the digestive tract, in: “Developments in the Science and Practice of Toxicology,” A. W. Hayes, R. C. Schnell, and T. S. Miya, eds., Elsevier, Amsterdam, p. 299.Google Scholar
  4. Cerutti, P. A., 1985, Prooxidant state and tumor promotion, Science, 227: 375.PubMedCrossRefGoogle Scholar
  5. Distlerath, L. M., and Guengerich, F. P., 1984, Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs using antibodies raised to the analogus rat enzyme, Proc. Natl. Acad. Sci. USA, 81:7348.PubMedCrossRefGoogle Scholar
  6. Dossing, M., 1982, Changes in hepatic microsomal enzyme function in workers exposed to mixtures of chemicals, Clin. Pharmacol. Ther., 32:340.PubMedCrossRefGoogle Scholar
  7. Farrell, G. C., Cooksley, W. G. E., and Powell, L. W., 1979, Drug metabolism in liver disease: Activity of hepatic microsomal metabolizing enzymes, Clin. Pharmacol. Ther., 26:488.Google Scholar
  8. Fujino, T., Park, S. S., West, D., and Gelboin, H. V., 1982, Phenotyping of cytochrome P-450 in human tissues with monoclonal antibodies, Proc. Natl. Acad. Sci. USA, 79:3682.PubMedCrossRefGoogle Scholar
  9. Held, H., 1980, Correlation between the activity of hepatic benzo(a)pyrene hydroxylase in human needle biopsies and the clearance of glymidine, Hepato-Gastroenterol., 27:266.Google Scholar
  10. Hetzel, M. R., Law, M., Keal, E. E., Sloan, T. P., Idle, J. R., and Smith, R. L., 1980, Is there a genetic component in bronchial carcinoma in smokers?, Thorax, 35:709.CrossRefGoogle Scholar
  11. Hietanen, E., Ahotupa, M., Heikelä, A., and Laitinen, M., 1982, Dietary lipids as modifiers of monooxygenase induction, in: “Cytochrome P-450, Biochemistry, Biophysics and Environmental Inplications,” E. Hietanen, M. Laitinen, and O. Hänninen, eds., Elsevier, Amsterdam, p. 705.Google Scholar
  12. Hietanen, E., Bartsch, H., Ahotupa, M., Park, S. S., and Gelboin, H. V., 1985 a, Tissue specificity of extrahepatic monooxygenases in the metabolism of xenobiotics, in: “Proc. 9th European Workship on Drug Metabolism,” G. Siest, ed., Pergamon Press, Londor, p. 141.Google Scholar
  13. Hietanen, E., Bartsh, H., Gastegnaro, M. Malaveille, C., Michelon, J., and Broussole, L., 1985 b, Use of antibodies against cytochrome P-450 isozymes to study genetic polymorphism in drug oxidations. Submitted.Google Scholar
  14. Hietanen, E., Malaveille, C., Camus, M.-C., Béréziat, J. C., Brun, G., Gastegnaro, M., Michelon, J., Idle, J. R., and Bartsch, H., 1985 c, Interstrain comparison of hepatic and renal microsomal carcinogen metabolism and liver S9 mediated mutagenicity in DA and Lewis rats phenotyped as poor and extensive metabolizers of debrisoquine. Submitted.Google Scholar
  15. Hietanen, E., Malaveille, C., Friedman, F. K., Park, S. S., Béréziat, J. C., Brun, G., Bartsch, H., and Gelboin, H. V., 1985 d, Monoclonal antibody directed analysis of cytochrome P-450 dependent monooxygenases and muta-gen activation in the livers of D2 and B6 mice. Submitted.Google Scholar
  16. Idle, J. R., Mahgoub, A., Lancaster, R., and Smith, R. L., 1978, Hypotensive response to debrisoquine and hydroxylation phenotype, Life Sci., 22:979.PubMedCrossRefGoogle Scholar
  17. Idle, J. R., Mahgoub, A., Lancaster, R., Smith, R. L., Mbanefo, C. O., and Bababunmi, E. A., 1981, Some observations on the oxidation phenotype status of Nigerian patients presenting with cancer, Cancer Lett., 11: 331.PubMedCrossRefGoogle Scholar
  18. International Agency for Research on Cancer, 1982, IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, Suppl. 4, Lyon.Google Scholar
  19. Jusko, W., 1982, Role of tobacco smoking in pharmacokinetics, J. Pharmacokin. Biopharmaceut., 6:7.CrossRefGoogle Scholar
  20. Kalow, W., 1982, The metabolism of xenobiotics in different populations, Can. J. Physiol. Pharmacol., 60:1.PubMedCrossRefGoogle Scholar
  21. Kalow, W., Otton, S. V., Kadard, D., Endrenyi, L., and Inaba, T., 1980, Ethnic differences in drug metabolism: debrisoquine 4-hydroxylation in Caucasians and Orientals, Can. J. Physiol. Pharmacol., 58:1142.PubMedCrossRefGoogle Scholar
  22. Kaminsky, L. S., Dunbar, D. A., Wang, P. P., Beaune, P., Larrey, D., Guengerich, F. P., Schnellman, R. G., and Sipes, I. G., 1984, Human hepatic cytochrome P-450 composition as probed by in vitro microsomal metabolism of warfarin, Drug Metab. Dispos., 12:470.PubMedGoogle Scholar
  23. Kappas, A., Anderson, K. E., Ionney, A. H., Pantuck, E. J., Fishman, J., and Braddow, H. L., 1983, Nutrition-endocrine interacitons: Induction of reciprocal changes in the 44–5a-reducton of testosterone and the cytochrome P-450-dependent oxidation of estradiol by dietary macronutrients in man, Proc. Natl. Acad. Sci. USA, 80:7646.PubMedCrossRefGoogle Scholar
  24. Kellermann, G., and Luyten-Kellermann, M., 1977, Phenobarbitalinduced drug metabolism in man, Toxicol. Appl. Pharmacol., 39:97.PubMedCrossRefGoogle Scholar
  25. Kellermann, G. H., and Luyten-Kellermann, M., 1978, Antipyrine metabolism in man, Life Sci., 23:2485.PubMedCrossRefGoogle Scholar
  26. Kauppila, A., Sundström, H., Korpela, H., Viinikka, L., and Yrjönheikki, E., 1984, Serum selenium and gynecological cancer, in: “Icosanoids and Cancer,” H. Thaler-Dao, A. Crasted de Paulet, and R. Paoletti, eds., Raven Press, New York, p. 263.Google Scholar
  27. Larrey, D., Distlerath, L. M., Dannan, G. A., Wilkinson, G. R., and Guengerich, P. F., 1984, Purification and characterization of the rat liver microsomal cytochrome P-450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism, Biochemistry, 23:2784.CrossRefGoogle Scholar
  28. Levine, A. S., McKinney, C. E., Echelberger, C. K., Kouri, R. E., Edwards, B. K., and Nebert, D. W., 1984, Aryl hydrocarbon hydroxylase inducibility among primary relatives of children with leukemia or solid tumours, Cancer Res., 44:358.PubMedGoogle Scholar
  29. Mahgoub, A., Idle, J. R., Dring, L. G., Lancaster, R., and Smith, R. L., 1977, Polymorphic hydroxylation of debrisoquine in man, Lancet, 2:584.PubMedCrossRefGoogle Scholar
  30. Miller, E. C., and Miller, J. A., 1966, Mechanisms of chemical carcinogenesis: Nature of proximate carcinogen and interactions with macromolecules, Pharmacol. Rev., 18:805.Google Scholar
  31. Pantuck, E. J., Hsiao, K. C., Conney, A. H., Garland, W. A., Kappas, A., Anderson, K. E., and Alvares, A. P., 1976, Effect of charcoal-broiled beef on phenacetin metabolism in man, Science, 194:1055.PubMedCrossRefGoogle Scholar
  32. Park, S. S., Fujino, T., West, D., Guengerich, F. P., and Gelboin, H. V., 1982, Monoclonal antibodies that inhibit enxyme activity of 3-methylcholanthrene-induced cytochrome P-450, Cancer Res., 42:1798.PubMedGoogle Scholar
  33. Pelkonen, O., and Kärki, N. T., 1982, Is aryl hydrocarbon hydroxylase induction “systemically” regulated in man, in: “Host Factors in Human Carcinogenesis” (IARC Scientific Publications No. 39) H. Bartsch and B. Armstrong, eds., International Agency for Research on Cancer, Lyon, p. 421.Google Scholar
  34. Penno, M. B., and Vesell, E., S., 1983, Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation, J. Clin. Invest., 71:1698.Google Scholar
  35. Poland, A., Glover, E., Robinson, J. R., and Nebert, D. W., 1974, Genetic expression of aryl hydrocarbon hydroxylase activity: induction of monooxygenase activities and cytochrome P-450 formation by 2,3,7,8,-tetrachlorodibenzo-p-dioxin in mice genetically “nonresponsive” to other aromatic hydrocarbons, J. Biol. Chem., 249:5599.PubMedGoogle Scholar
  36. Prince-Evans, D. A., Mahgoub, A., Sloan, T. P., Idle, J. R., and Smith, R. L., 1980, A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population, J. Med. Genet., 17:102.CrossRefGoogle Scholar
  37. Ritchie, J. C., Crothers, M. J., Idle, J. R., Freig., J. B., Connors, T. A., Nikolov, J. G., and Chernozemsky, J. N, 1983, Evidence for an inherited metabolic susceptibility to endemic (Balkan) nephropathy, in: “Current Research in Endemic (Balkan) Nephropathy,” S. Strahijic and V. Stefanovic, eds., NIS, Bulgaria, pp. 23–27.Google Scholar
  38. Ritchie, J. C., and Idle, J. R., 1982, Population studies of polymorphism in drug oxidation and its relevance to carcinogenesis, in: “Host Factors in Human Carcinogenesis” (IARC Scientific Publications No. 39). S Bartsch, and B. Armstrong, eds., International Agency for Research on Cancer, Lyon, p. 338.Google Scholar
  39. Röschenthaler, R., Creppy, E. E., and Dirheimer, G. G., 1984, Ochratoxin: mode of action of a ubiquitous mytoxin, J. Toxicol. Toxin Rev., 3:53.Google Scholar
  40. Schneider, J. F., Baker, A. L., Haines, N. W., Hatfield, G., and Boyer, J. L., 1980, Aminopyrine N-demethylation: A prognostic test of liver function in patients with alcoholic liver disease, Gastroenterology, 79:1145.PubMedGoogle Scholar
  41. Sotaniemi, E. A., Pelkonen, R. O., and Puukka, M., 1980, Measurement of hepatic drug-metabolizing enzyme activity in man, Eur. J. Clin. Pharmacol., 17:267.PubMedCrossRefGoogle Scholar
  42. Vainio, H., and Hietanen, E., 1980, Role of extrahepatic metabolism, in: “Concepts in Drug Metabolism,” B. Testa and P. Jenner, eds., vol. 1, Marcel Dekker, New York, p. 281.Google Scholar
  43. Vesell, E. S., 1982, Complex, dynamically interactig host factors that affect the disposition of drug and carcinogens, in: “Host Factors in Human Carcinogenesis” (IARC Scientific Publications No. 39), H. Bartsch and B. Armstrong, eds., International Agency for Research on Cancer, Lyon, p. 427.Google Scholar
  44. Vestal, R. E., and Wood, A. J. J., 1979, Influence of age and smoking in drug kinetics in man. Studies using model compounds, Clin. Pharmacokin., 5: 309.CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1986

Authors and Affiliations

  • E. Hietanen
    • 1
  • H. Bartsch
    • 1
  • H. Vainio
    • 1
  1. 1.Division of environmental carcinogenesisInternational Agency for Research on CancerLyon Cedex 08France

Personalised recommendations